Ratings Pfizer Limited Bombay S.E.

Equities

PFIZER

INE182A01018

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-07-04 am EDT			5-day change	1st Jan Change
4,625 ^INR	+0.82%		+2.10%	+8.35%

May. 30	Pfizer Limited Receives an Order Issued by the Joint Commissioner of Sate Tax, Raipur Division 1: Chhattisgarh	CI
May. 17	Pfizer Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With an expected P/E ratio at 41.84 and 34.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PFIZER LIMITED	+8.35%	2.51B	C
ELI LILLY AND COMPANY	+54.07%	809B	C+
NOVO NORDISK A/S	+39.62%	621B	B
JOHNSON & JOHNSON	-7.05%	351B	C+
MERCK & CO., INC.	+15.44%	319B	B-
ABBVIE INC.	+5.72%	289B	C+
ASTRAZENECA PLC	+14.75%	238B	B+
ROCHE HOLDING AG	-0.57%	221B	A+
NOVARTIS AG	+14.50%	218B	B-
AMGEN INC.	+7.42%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes